Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Risedronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 11/20 | 0.80 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.80 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Risedronic Acid SCHEMBL3781658 | 0.92 | FDPS (0.71) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL29380338 | 0.91 | FDPS (0.80) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL18377 | 0.91 | FDPS (0.80) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL5176322 | 0.91 | FDPS (0.70) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL536966 | 0.90 | FDPS (0.78) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL29738088 | 0.90 | FDPS (0.78) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL4755300 | 0.90 | FDPS (0.78) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL4643040 | 0.90 | FDPS (0.83) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL5970387 | 0.90 | FDPS (0.78) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL3953153 | 0.90 | FDPS (0.78) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276604-B2 | Crystalline form of the sodium salt of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid | ZENTIVA A.S. (CZ) | 2007-10-02 | — | — | US | disclosed |
| EP-1556041-B1 | NEW CRYSTALLINE HYDRATES OF THE SODIUM SALT OF 3-PYRIDYL-1-HYDROXYETHYLIDENE-1,1-BISPHOSPHONIC ACID | ZENTIVA AS (CZ) | 2007-08-29 | — | — | EP | disclosed |
| US-20060148762-A1 | New crystalline form of the sodium salt of 3-pyridyl-1-hydroxyehtylidene-1,1-bisphosphonic acid | ZENTIVA, A.S. (CZ) | 2006-07-06 | — | — | US | disclosed |
| EP-1556041-A1 | A NEW CRYSTALLINE FORM OF THE SODIUM SALT OF 3-PYRIDYL-1-HYDROXYETHYLIDENE-1,1-BISPHOSPHONIC ACID | Zentiva, A.S. (CZ) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004037252-A1 | A NEW CRYSTALLINE FORM OF THE SODIUM SALT OF 3-PYRIDYL-1-HYDROXYETHYLIDENE-1,1-BISPHOSPHONIC ACID | ZENTIVA, A.S. (CZ) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148762-A1 | New crystalline form of the sodium salt of 3-pyridyl-1-hydroxyehtylidene-1,1-bisphosphonic acid | SLC20A1, SLC9A1, PHPT1 | FDPS 1818/4885BTN3A1 1266/4885PDE3A 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.